Polsinelli Podcasts - FDA Denies Amgen Citizen Petition in Biosimilar Dispute
Patent owners generally look to secondary indicia to bolster their nonobvious defenses when prior art and/or knowledge of a person of ordinary skill in the art (“POSA”) seem to make the obviousness decision a close call. This...more